Loading…
BioMarin Pharmaceutical Inc. is projected to rise to $68.79 by 2027, a +31% move from its current price of $52.38. BMRN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $51.41 | $52.39 | $53.39 | +0.02% |
| May 30 | $51.02 | $52.40 | $53.81 | +0.03% |
| May 31 | $50.72 | $52.40 | $54.15 | +0.05% |
| Jun 1 | $50.47 | $52.41 | $54.43 | +0.06% |
| Jun 2 | $50.25 | $52.42 | $54.68 | +0.08% |
| Jun 3 | $50.06 | $52.43 | $54.91 | +0.09% |
| Jun 4 | $49.88 | $52.44 | $55.12 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $49.88 | $52.44 | $55.12 | +0.11% |
| Week 2 | $48.91 | $52.49 | $56.34 | +0.22% |
| Week 3 | $48.20 | $52.55 | $57.30 | +0.33% |
| Week 4 | $47.61 | $52.61 | $58.14 | +0.44% |
| Week 5 | $47.10 | $52.67 | $58.89 | +0.54% |
| Week 6 | $46.65 | $52.72 | $59.59 | +0.65% |
| Week 7 | $46.25 | $52.78 | $60.24 | +0.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for life-threatening rare diseases and medical conditions across the United States, Europe, Latin America, the Middle East, the Asia Pacific, and international markets. Its portfolio includes VIMIZIM, an enzyme replacement therapy for mucopolysaccharidosis IV type A; VOXZOGO, a once-daily injection analog of CNP for achondroplasia; NAGLAZYME for MPS VI; PALYNZIQ to reduce blood phenylalanine; BRINEURA for Batten disease; ALDURAZYME; and KUVAN for phenylketonuria.
The company also develops BMN 333 and BMN 351. BioMarin has license and collaboration agreements with Ares Trading S.A. Incorporated in 1996, the company is based in San Rafael, California.
BioMarin, ticker BMRN, currently trades at $54.09 per share and holds a market cap of $10.45B, ranking 890 by market capitalization. The current price sits near its 50-day and 200-day moving averages, suggesting a balanced near-term stance. The forecast shows a rising price trajectory with an average of $93.17 by 2030 and potential highs of $127.94, accompanied by a projected ROI of 72.3% in that year.
A major floor 10.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.2% below — buyers have tended to step in here.
The nearest ceiling, 5.9% above — a clean break opens room to run.
A major ceiling 22.3% above — clearing it would confirm fresh momentum.
Key BMRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $52.73 | Sell | $52.61 | Sell |
| MA 10 | $52.17 | Buy | $52.56 | Sell |
| MA 20 | $53.04 | Sell | $52.96 | Sell |
| MA 50 | $54.25 | Sell | $54.33 | Sell |
| MA 100 | $56.63 | Sell | $55.42 | Sell |
| MA 200 | $55.85 | Sell | $56.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.14 | Neutral |
| Stoch RSI (14) | 68.58 | Neutral |
| CCI (20) | -36.41 | Neutral |
| Williams %R (14) | -39.10 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | -3.11 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 60.90 | Neutral |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | -0.92 | Sell |
| Ultimate (7,14,28) | 48.99 | Neutral |
| Momentum (10) | -0.50 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 53.89 | Sell |
| ADX (14) | 14.88 | Neutral |
| ATR (14) | 0.93 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 is 50, indicating a neutral momentum. The 50-day simple moving average is $54.46 and the 200-day simple moving average is $55.91, implying a slight tilt toward stability near the current level. Support is cited at $49.67 and resistance at $55.47, framing a near-term trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $49.67 | $52.38 | $68.41 | 0% | Neutral | |
| $56.19 | $68.79 | $88.15 | +31% | Bullish | |
| $62.70 | $78.17 | $102.79 | +49% | Bullish | |
| $62.26 | $78.79 | $105.78 | +50% | Bullish | |
| $68.72 | $88.13 | $120.41 | +68% | Bullish | |
| $70.46 | $91.46 | $126.91 | +75% | Bullish | |
| $71.80 | $94.24 | $132.61 | +80% | Bullish | |
| $88.34 | $117.17 | $166.99 | +124% | Bullish | |
| $95.45 | $127.85 | $184.38 | +144% | Bullish | |
| $98.14 | $132.70 | $193.49 | +153% | Bullish | |
| $136.22 | $192.09 | $293.44 | +267% | Bullish | |
| $219.41 | $331.82 | $543.27 | +533% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $49.67 | $52.38 | $61.30 | +0.00% |
| June 2026 | $45.66 | $53.26 | $63.34 | +1.68% |
| July 2026 | $45.28 | $53.13 | $63.78 | -0.25% |
| August 2026 | $44.00 | $51.86 | $62.71 | -2.39% |
| September 2026 | $44.39 | $52.52 | $63.88 | +1.27% |
| October 2026 | $45.87 | $54.45 | $66.60 | +3.68% |
| November 2026 | $46.11 | $54.90 | $67.46 | +0.82% |
| December 2026 | $46.42 | $55.42 | $68.41 | +0.96% |
Click any year to see its month-by-month BMRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BMRN to range from $49.67 to $68.41 through 2026. The $52.38 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BMRN price prediction for 2027 points to an average of $68.79 (low $56.19, high $88.15) — a potential gain of +31% on today's $52.38. Buyers look set to stay in control over this stretch.
In 2028, BMRN is projected to trade between $62.70 and $102.79, averaging $78.17 — a potential gain of +49% from today's $52.38. That is up +14% on the projected 2027 average. Momentum favours further upside here.
BioMarin Pharmaceutical Inc.'s 2029 outlook centres on $78.79, within a $62.26 to $105.78 range. That is up +1% on the projected 2028 average. That marks a +50% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, BMRN could reach as high as $120.41, with a base case around $88.13 and support toward $68.72 — roughly +68% from $52.38. Momentum favours further upside here.
Expect BMRN to range from $70.46 to $126.91 through 2031. The $91.46 average target implies a +75% move from current prices. That is up +4% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BMRN price prediction for 2032 points to an average of $94.24 (low $71.80, high $132.61) — a potential gain of +80% on today's $52.38. Momentum favours further upside here.
In 2033, BMRN is projected to trade between $88.34 and $166.99, averaging $117.17 — a potential gain of +124% from today's $52.38. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
BioMarin Pharmaceutical Inc.'s 2034 outlook centres on $127.85, within a $95.45 to $184.38 range. That is up +9% on the projected 2033 average. That marks a +144% change versus current levels. Momentum favours further upside here.
By 2035, BMRN could reach as high as $193.49, with a base case around $132.70 and support toward $98.14 — roughly +153% from $52.38. Buyers look set to stay in control over this stretch.
Expect BMRN to range from $136.22 to $293.44 through 2040. The $192.09 average target implies a +267% move from current prices. That is up +45% on the projected 2035 average. Momentum favours further upside here.
The BMRN price prediction for 2050 points to an average of $331.82 (low $219.41, high $543.27) — a potential gain of +533% on today's $52.38. Buyers look set to stay in control over this stretch.
Investing $1,000 in BMRN today (≈ 19.091256 BMRN) could be worth
$6,334.95
+$5,334.95 (+533%) by 2050 · US Dollar
Based on the average projected BMRN price of $331.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMRNwould be worth at today's price.
$1,000 invested in BMRN on May 27, 2025 (≈ 17.208742 BMRN) would be worth
$901.39
-$98.61 (-9.9%) today · 0.90× · US Dollar
Based on a BMRN entry price of $58.11 vs. today's $52.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $50.2 | $1,043.43 | +4.3% |
| 1 month ago | $53.81 | $973.42 | -2.7% |
| 3 months ago | $61.11 | $857.14 | -14.3% |
| 6 months ago | $55.93 | $936.53 | -6.3% |
| 1 year ago | $58.11 | $901.39 | -9.9% |
| All time (5.0y) ago | $77.69 | $674.22 | -32.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMRN forecast.
Our base-case forecast reaches $100.00 around 2033.
Implied market cap at $100.00: $19.33B
The multi-year forecast shows a bullish trajectory beyond 2026. For 2030 the avg price is $93.17 with a max of $127.94 and a ROI of 72.3%, signaling meaningful upside potential from today’s level. The 2040 forecast expects an avg of $205.82 with a ROI of 280.5% and a max of $316.85.
By 2050, the avg is projected at $363.29 with a ROI of 571.6% and a max of $600.32. The sequence includes rising averages and ROIs through 2027–2035, with 2033–2035 showing substantial acceleration and continued bullish sentiment. These are estimates and not guarantees, and the figures reflect inherent market volatility, including an annualized volatility around 40%.
Tap a question to reveal the answer.
The forecast for 2030 shows min $72.37, avg $93.17, max $127.94 with a ROI of 72.3% and sentiment BULLISH.
Forecasts show an upward trajectory with rising average prices and positive ROIs over time: 2027 ROI 33.2%, 2028 ROI 50.7%, 2029 ROI 53.4%, 2030 ROI 72.3%, 2040 ROI 280.5%, 2050 ROI 571.6%.
Yes. The 2030 max forecast is $127.94, which exceeds $120.
$47.57 to $61.50.
BioMarin Pharmaceutical Inc. Community Discussion
0Share your BioMarin Pharmaceutical Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.